Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...

Using individual patient data from phase 2 and 3 trials, investigators analyzed the value of pathologic complete response vs ctDNA clearance after neoadjuvant immunotherapy or perioperative ...

Rapid developments in muscle-invasive bladder cancer treatment are leading to new approaches to bladder preservation.

On Friday, the U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s PFE and Astellas Pharma Inc.’s ALPMF ALPMY ...

The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The ...

ASCO 2026 highlighted a shift toward precision-driven oncology R&D, where biomarkers, ctDNA, and integrated strategies guide ...

This feature explores evolving management strategies for bone sarcomas, highlighting multidisciplinary treatment approaches ...

Rilvegostomig plus T-DXd achieved 57% pCR in HR+/immune+ HER2-negative breast cancer in I-SPY 2.2, potentially enabling surgery without chemotherapy. In this study, R, a bispecific checkpoint ...

ATOS READ THE FULL ATOS RESEARCH REPORT Business Update Abstracts Presented at ASCO 2026 In June 2026, Atossa Therapeutics, Inc. (NASDAQ: ATOS) announced that two abstracts were presented at the 2026 ...

Pancreatic cancer's neoadjuvant debate is no longer about whether systemic therapy matters. It is about when to give it. The field is split between clinicians who view preoperative treatment as the ...

In this phase 3 trial, researchers aimed to characterize the clinical characteristics, treatment approaches, and outcomes of patients with metastatic non-rhabdomyosarcoma soft tissue sarcoma and to ...

Health experts have underlined that soft tissue sarcomas, a rare and complex group of cancers, require precise diagnosis, ...